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Introduction
In recent years, three separate papers in leading medical journals 
have raised the question of why co-trimoxazole prophylaxis for 
opportunistic infections in patients living with the human im-
munodeficiency virus (HIV) has not been more widely scaled 
up in low-income countries. Published in The Lancet Infectious 
Diseases,1 the BMJ2 and the Bulletin of the World Health Orga-
nization,3 these papers have all expressed the authors’ frustration 
at knowing that an intervention known to be highly efficacious, 
cost-effective, amply researched and urgently needed has not 
become widely available, especially in Africa. In the most recent 
article, Date et al. combined analyses of the development of 
policy on co-trimoxazole prophylaxis and on isoniazid preventive 
therapy to raise concerns about the uptake of both interven-
tions. While operationally the need to rule out active disease 
before initiating treatment creates problems that make isoniazid 
preventive therapy especially challenging, Date et al. highlight 
similarities in the frustration generated by the slow scale-up 
of both co-trimoxazole prophylaxis and isoniazid preventive 
therapy. They point out that at the national level both the de-
velopment of co-trimoxazole prophylaxis and the development 
and implementation of policy on isoniazid preventive therapy 
have been sluggish, and they argue that “strong advocacy and dis-
semination of evidence-based information regarding the benefits 
of co-trimoxazole prophylaxis and isoniazid preventive therapy 
are urgently required at the national and international level”.
Several efforts have been made internationally to improve 
the way in which research evidence is conveyed to health policy-
makers and to advocate for the bridging of the gap between 
evidence and policy. The Evidence Informed Policy Network, 
launched by the World Health Organization (WHO), is an 
example of an entity whose purpose is to promote these func-
tions (www.who.int/rpc/evipnet/en/). However, advocacy and 
dissemination can only go so far in influencing policy change 
and implementation in practice. As Date et al. explain, evidence-
based data on the benefits of both co-trimoxazole prophylaxis 
and isoniazid preventive therapy has not been lacking interna-
tionally. The findings from the first studies conducted on co-
trimoxazole prophylaxis were published in the Lancet as early 
as 19994,5 and subsequent studies showed that co-trimoxazole 
prophylaxis was beneficial in adults and children in areas of 
high resistance to co-trimoxazole6–8, as well as in adults on anti-
retroviral therapy (ART).9 Research on the efficacy of isoniazid 
preventive therapy began even earlier and has already been the 
subject of three Cochrane reviews.10–12 Beyond these research 
findings, the Joint United Nations Programme on HIV/AIDS, 
WHO and the United Nations Children’s Fund have all issued 
guidelines on the use of co-trimoxazole prophylaxis on three 
different occasions,13–15 while isoniazid preventive therapy was 
the subject of WHO recommendations first published in 1998 
and later reaffirmed by the Stop TB partnership in 2007 and 
2011.16–18
In these examples, research findings were available and in 
many cases had been clearly disseminated or advocated for by 
the research and international public health communities. Those 
who feel frustrated by the lack of uptake of research results and 
the apparent stalling of policy development must understand the 
Abstracts in بيرع, 中文, Français, Pусский and Español at the end of each article.
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need to move beyond the assumption that 
the epidemiological and cost-effectiveness 
data that are available, once communi-
cated, will be automatically integrated 
into policy. Broader analyses are needed 
to support researchers as they seek to 
get clinically effective interventions into 
place. Such analyses require established 
methods and frameworks from the field 
of policy analysis to improve the under-
standing of the process of health policy 
development in a given national and 
international context. Those who look 
with consternation on the lack of uptake 
of available health research evidence for 
guiding policy and practice need to en-
gage more explicitly with policy analysis 
approaches. While efforts to bridge the 
gap between researchers and policy-
makers are important, decision-making, 
by its very nature, calls for many other 
factors to be considered; communicating 
the evidence is not enough.
Between September 2008 and March 
2010, we conducted a policy analysis in 
three sub-Saharan African countries (Ma-
lawi, Uganda and Zambia) for the pur-
pose of studying the processes involved 
in the formulation of national policies 
on co-trimoxazole prophylaxis. By doing 
so we hoped to explain the factors that 
hindered or facilitated the translation of 
clinical and cost effectiveness data into 
national policy. To expand on this work, 
members of our research team are cur-
rently investigating the implementation 
of co-trimoxazole prophylaxis by applying 
a policy implementation lens to better 
understand the factors that shape the 
uptake of national policies among service 
providers in these settings.
Our work has focused on policy 
structures and process to which differ-
ences in the uptake and timing of the 
translation of research into policy have 
been attributed in non-health sectors 
in developing countries. We selected 
the study countries through purposive 
sampling. This was done because all 
countries had hosted high-profile research 
projects on the efficacy of co-trimoxazole 
prophylaxis, yet their policy processes 
had unfolded in different ways. Of the 
three countries, Malawi had the first 
national policy on co-trimoxazole pro-
phylaxis (published in 2002) but limited 
the intervention to HIV-positive (HIV+) 
patients with tuberculosis. Uganda fol-
lowed in April 2005 with a policy for 
all HIV+ patients, while that same year 
Malawi broadened its policy to include all 
HIV+ positive patients (with or without 
tuberculosis). In Zambia, the need for a 
co-trimoxazole prophylaxis policy was 
agreed on at the national level in 2006 
and detailed guidelines were issued in 
2007. However, in all settings questions 
remain about the implementation process 
and our ongoing and future work will 
address these questions, as there is a lack 
of rigorous data on the extent to which 
co-trimoxazole prophylaxis has been 
implemented in resource-poor settings. 
This question is being addressed by an-
other study undertaken by the Medical 
Research Council Clinical Trials Unit of 
the United Kingdom of Great Britain and 
Northern Ireland.
In our work on research evidence 
uptake, we used a framework originally 
developed by the Overseas Development 
Institute for resource-poor settings to 
identify the country-specific elements 
influencing the uptake of co-trimoxazole 
prophylaxis and to identify common-
alities. The framework conceptualises the 
uptake of research in policy development 
as a function of three key elements: (i) the 
national health care context (with due at-
tention to the influence that global policy 
and development agencies may exercise at 
the national level in sub-Saharan Africa); 
(ii) the networks and links between the 
individuals involved in research and 
policy-making, and (iii) the nature of the 
evidence available (including the different 
ways in which different actors may inter-
pret it).19,20 This framework, focused on 
the context, the human links and the evi-
dence, guided qualitative inquiry among 
key individuals involved in the policy de-
velopment process and enabled us to map 
the processes by which co-trimoxazole 
prophylaxis was taken up in different set-
tings. It also allowed us to identify both 
the stable and the dynamic elements that 
appeared to either facilitate or hinder 
that process in each country. Our critical 
ongoing work on policy implementation 
will assess current practice, in quantitative 
and qualitative terms, surrounding the 
provision of co-trimoxazole prophylaxis 
for eligible patients. This work will also 
document the barriers to the implementa-
tion of co-trimoxazole prophylaxis faced 
by facility-level health-care providers.
Context, links and evidence 
in practice
In each of our study countries, the politi-
cal and economic context was found to 
influence how co-trimoxazole prophylaxis 
evidence was interpreted locally and how 
useful the results of research were per-
ceived to be from the standpoint of the 
country’s needs. At its most simple, if re-
search is not a priority within a particular 
government programme, it is unlikely that 
research findings will make their way into 
policy. Politicized and highly publicized 
debates about other health issues, such 
as the discussions around ART therapy 
for HIV+ patients that dominated the 
agenda in Zambia for some time, can also 
obscure other, less widely known research 
findings.
But just as some policy contexts can 
hinder the uptake of research results for 
policy-making, others can be more con-
ducive to such uptake. For example, while 
Malawi had very little money for scaling 
up activities for the treatment of HIV+ 
individuals at the turn of the century, the 
National TB Control Programme was ac-
tively looking for biomedical approaches 
to reduce HIV-related deaths among 
tuberculosis patients. The research on 
the efficacy of co-trimoxazole prophylaxis 
for HIV+ patients with tuberculosis was 
conducted in close collaboration with the 
national tuberculosis control programme. 
The findings were quickly translated into 
policy and implemented within an exist-
ing and smoothly functioning national 
tuberculosis control programme with 
plentiful resources.
Beyond context, however, the three 
countries revealed the important role 
played by key actors – so-called “policy 
entrepreneurs”– in facilitating the uptake 
of policy or in moving the policy-making 
process forward. Research results may 
well be known about within policy circles; 
but unless a key actor presents the data, 
addresses other policy-makers’ concerns 
and makes sure that the item remains a 
priority on the agenda, efforts can stall 
early in the policy development phase. In 
all our study countries, successful policy 
entrepreneurs were found to be well con-
nected to critical national networks, 
both in the research and policy-making 
community. When such actors are well 
positioned, they can pull networks closer 
together and forge links by introducing 
key individuals.
Finally, the type of evidence available 
and the perception of its significance 
are central to the ways in which policy-
making agendas are developed. While 
scientists harbour the notion that evi-
dence should speak for itself, it very often 
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does not. For the evidence to be taken up 
and converted into policy, it is necessary 
for someone to convey it in the right 
way. So, for instance, the case in favour 
of co-trimoxazole prophylaxis may have 
simply been framed in a manner that was 
not conducive to a change of policy in 
Zambia. Since co-trimoxazole was already 
a well known and readily used medication, 
at first the new evidence was perceived as 
relevant for clinical practice rather than 
for national policy. A reframing of co-
trimoxazole prophylaxis as a policy issue 
in and of itself was needed in this case to 
facilitate policy action.
Discussion
To understand how evidence gets taken 
up and integrated into policy, and how 
policy, in turn, translates into practice, 
we need to find ways to move beyond the 
assumption that policy and practice will 
directly follow from the dissemination 
of convincing scientific findings, or that 
implementation is straightforward and 
a simple matter of scaling up a policy 
decision. Political realities and national 
contexts influence policy development, 
but well established policy analysis ap-
proaches make it possible to identify and 
analyse these influences. They further al-
low the development of context-specific 
explanations for particular situations. The 
case of co-trimoxazole prophylaxis pro-
vides a clear example of this and affords 
several lessons that can be applied in deal-
ing with the similar challenges posed by 
the scale-up of other treatments, such as 
isoniazid preventive therapy.
After several epidemiological and 
cost-effectiveness studies and multiple 
recommendations from international 
organizations, questions are still raised as 
to why the uptake of co-trimoxazole pro-
phylaxis and isoniazid preventive therapy 
in low-income settings was so slow. In 
the case of co-trimoxazole prophylaxis, 
evidence uptake was inconsistent. To 
explain the individual response of each 
country would require an analysis of 
various aspects of the local context, the 
institutional and human networks in 
place, the way the evidence was framed 
and the roles of key policy entrepreneurs. 
Explaining implementation requires 
an understanding of local constraints 
(e.g. lack of funds and resources or the 
high turnover of health ministry staff ) 
and of the contexts in which the policy 
was applied. There is no simple formula 
for improving the uptake of research 
findings, but a better understanding of 
these elements can help researchers and 
advocates in ensuring more rapid uptake 
of research results favouring interventions 
such as isoniazid preventive therapy. We 
hope that our work has succeeded in 
illustrating the importance of a policy 
analysis perspective for researchers in 
similar settings concerned with getting 
their findings integrated into policy. ■
Competing interests: None declared.
صخللما
لوزاسكويمرتوكلاب ةيئاقولا ةجلاعلما نم سورد :لخدلا ةضفخنلما نادلبلا في تاسايس لىإ تانّيبلا ةمجرت
 ،ةلجلما نم 2010 ليربأ/ناسين في رداصلا ددعلا في ،هاكشرو Date تاد ّربع
 ينشياعملل  ةيزاهتنلاا  ىوادعلل  ينيئاقو ينجلاع ميمعت  ءطب نم مهقلق  نع
 ةيقوتلا  :ماهو  لخدلا  ةضفخنلما  نكاملأا  في  يشربلا  يعانلما  زوعلا  سويرفل
 ةلاقلما  هذه  شقانتو  .ديزاينوزيلأاب  ةيئاقولا  ةجلاعلماو  ،لوزاسكويمرتوكلاب
 تاسايسلا ليلحت نم ةدافتسلاا اهقيرط نع نكيم يتلا ةماهلا قرطلا ةيرصقلا
 تاسايسلا  في  ةددحلما  تانّريبلا  قيبطتل  ليبسلا  داجيإ  ةيفيك  حشرو  م ّرهفتل
 ىقَتسُتو  .ةيلمعلا  هذه  لىع  رثؤت  يتلا  ةيلحلما  لماوعلا  يأو  ،تاسرمالماو
 ةيقوتلا  لوح  ثوحبلا  تانّريب  نم  تاسايسلا  دادعإ  نع  ةيسيئرلا  سوردلا
 ةدعاسم  في  اهاودج  تبثت  نأ  نكبم  سوردلا  هذه  نلأ  ،لوزاسكويمرتوكلاب
 ديزاينوزيلأاب ةيئاقولا ةجلاعلما لوح ةينطولا تاسايسلا دادعإ لىإ نوعسي نم
 وحن لىع مهثوحب جئاتن شرن لىع ينثحابلا عيجشت يرجيو .ىرخلأا تاجلاعلاو
 ،ةيسسؤلماو ،ةّريوينبلا لماوعلا رـّرثؤت فيك اوعاري نأ ًاضيأ مهيلع نكلو ،حضاو
 م ّرهفتلا  في  كلذ  مهدعاسيسو  .تاسايسلا  ذيفنتو  دادعإ  لىع  ةيسايسلاو
 ميمعت نإو .ءابخلا رئاسو ،هاكشرو تاد اهركذ يتلا قلقلا رعاشلم ي ّردصتلاو
 لىع ةيلحلما لماوعلا رثؤت فيك حشرت يتلا ،تاسايسلا ليلحت بيلاسأ ةاعارم
 نورعشي نيذلا ينثحابلل ةيفاضإ ةادأ م ّردقي نأ نكيم ،ثوحبلا تانّريب ذاختا


















Traduire les preuves en politique dans les pays à faible revenu: leçons tirées de la thérapie préventive au 
cotrimoxazole
Dans l’édition d’avril 2010 de cette revue, Date et al. ont exprimé leur 
inquiétude quant à la lenteur de la généralisation, dans les pays à faible 
revenu, de deux thérapies de prévention des infections opportunistes 
chez les personnes vivant avec le virus de l’immunodéficience humaine: 
la prophylaxie par le cotrimoxazole et la thérapie préventive à l’isoniazide. 
Ce court article décrit de quelles façons importantes l’analyse de la 
politique peut s’avérer utile pour comprendre et expliquer comment et 
pourquoi certaines preuves s’intègrent à la politique et à la pratique, 
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et quels facteurs locaux influencent ce processus. Les leçons clés de 
l’élaboration des politiques sont tirées des preuves des recherches 
réalisées sur la prophylaxie au cotrimoxazole car ces leçons peuvent servir 
aux personnes qui souhaitent influencer le développement de la politique 
nationale en matière de thérapie préventive à l’isoniazide et d’autres 
traitements. Les chercheurs sont encouragés à diffuser leurs découvertes 
d’une manière claire, mais ils doivent également rester attentifs à la 
façon dont les facteurs structurels, institutionnels et politiques façonnent 
le développement et l’application des politiques. Ce faisant, ils pourront 
comprendre et résoudre les problèmes soulevés par Date et al., mais aussi 
par d’autres experts. L’intégration des approches d’analyse des politiques, 
qui expliquent comment les facteurs locaux modèlent la compréhension 
des preuves des recherches, peut fournir un outil supplémentaire aux 
chercheurs frustrés par le fait que les résultats de leurs recherches ne 
trouvent pas leur aboutissement dans la politique et la pratique.
Резюме
Воплощение научных данных в политические мероприятия в странах с низким доходом: уроки 
превентивной терапии котримоксазолом
В статье Dale et al., опубликованной в апрельском номере 
нашего журнала за 2010 год, была выражена озабоченность 
в связи с медленным распространением в странах и районах 
с низким доходом двух методов лечения, направленных 
на профилактику оппортунистических инфекций у 
больных, живущих с вирусом иммунодефицита человека: 
профилактического приема котримоксазола и превентивной 
терапии исониазидом. В нашей небольшой статье 
обсуждаются важные способы применения прикладного 
политического анализа для понимания и объяснения того, 
как и почему конкретные результаты научных исследований 
воплощаются в политику и практику, и какие местные 
факторы влияют на этот процесс. На основе результатов 
научных исследований, посвященных профилактическому 
приему котримоксазола, формулируются ключевые выводы, 
касающиеся разработки политических мероприятий. Они 
могут оказаться полезными для тех, кто стремится повлиять 
на формирование национальной стратегии в области 
превентивной терапии исониазидом и других методов 
лечения. Необходимо, чтобы ученые распространяли 
результаты своих исследований в понятной форме, однако 
они также обязаны обращать внимание на то, каким образом 
структурные, институциональные и политические факторы 
оказывают определяющее воздействие на разработку и 
внедрение политических мероприятий. Это поможет им 
понять и решить проблемы, поднятые Date et al. и другими 
экспертами. Широкое применение концепций прикладного 
политического анализа, объясняющих, как местные 
факторы формируют отклик на результаты научных 
исследований, может расширить инструментарий ученых, 
которые чувствуют себя разочарованными тем, что выводы 
их исследований не нашли применения в политике и на 
практике.
Resumen
Conversión de datos en planes de acción en los países de ingresos bajos: el tratamiento preventivo con la 
asociación de trimetroprim y sulfametoxazol como ejemplo
En la edición de abril de 2010 de esta publicación, Date et al. expresaron 
su preocupación por el lento progreso, en los países de ingresos bajos, 
de dos tratamientos preventivos de las infecciones oportunistas en 
personas con el virus de la inmunodeficiencia humana: la profilaxis con 
la asociación de trimetroprim y sulfametoxazol y el tratamiento preventivo 
con isoniazida. Este breve artículo aborda la importancia de la utilización 
del análisis de los planes de acción para entender y explicar cómo y por 
qué determinadas evidencias se introducen en las políticas y se llevan a 
la práctica y qué factores locales influyen en este proceso. Las lecciones 
principales de la elaboración de políticas se extraen de las investigaciones 
basadas en la evidencia de la profilaxis con la asociación de trimetroprim 
y sulfametoxazol, y dichas lecciones pueden resultar muy útiles a quienes 
deseen influir en el desarrollo de políticas nacionales sobre el tratamiento 
preventivo con isoniazida y otros tratamientos. Se insta a los investigadores 
a divulgar sus hallazgos de una manera clara, pero también deben prestar 
atención a la manera en que los factores estructurales, institucionales y 
políticos perfilan el diseño y la puesta en marcha de dichas políticas. De 
esta manera les resultará más fácil entender y abordar las inquietudes 
manifestadas por Date et al. y otros expertos. Aquellos investigadores que 
puedan sentirse frustrados porque los hallazgos de sus investigaciones 
no se hayan materializado en un plan de acción ni se hayan puesto en 
práctica, pueden valerse de una herramienta adicional: los métodos 
establecidos para el análisis político que explican cómo los factores locales 
moldean la aplicación de los datos científicos.
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